Biotech Stocks

Roth Capital Sees Downside in Dendreon Corporation Shares

In a research note issued today, Roth Capital reiterated coverage with a “Sell” rating on Dendreon Corporation (DNDN) and lowered its price target to $0.50 from …

Maxim Group Assumes Advanced Cell Technology at Buy

In a research note released today, Maxim Group assumed coverage on Advanced Cell Technology, Inc. (ACTC) with a Buy rating and a price …

Roth Capital Reaffirms EnteroMedics at Buy; Positive Bias Heading Into The FDA Panel

In a research note issued today, Roth Capital reiterated coverage with a “Buy” rating on EnteroMedics Inc. (ETRM), and a price target of $3.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts